Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more
Elevation raises $65M series B, names Leland CEO
Elevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant Asset Management; fellow new investors Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management and BVF Partners also participated. The company emerged from stealth in July with a tumor-agnostic mAb in Phase II testing for solid tumors. Aisling Capital's Steve Elms, who was serving as interim CEO, will remain chair.
Pharvaris closes $80M series C
Pharvaris GmbH raised $80 million in a series C round led by Viking Global Investors and General Atlantic. Fellow new investor Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock Healthcare Capital Partners joined the round. The company is developing a pipeline of oral BDKRB2 antagonists for hereditary angioedema; its lead program is slated to begin Phase II testing next year. ...